CLINICAL TRIALS PROFILE FOR LY3214996
✉ Email this page to a colleague
Clinical Trials for LY3214996
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT02857270 ↗ | A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer | Active, not recruiting | Eli Lilly and Company | Phase 1 | The purpose of this study is to determine the safety of an extracellular signal regulated kinase (ERK1/2) inhibitor LY3214996 administered alone or in combination with other agents in participants with advanced cancer. |
| NCT04033341 ↗ | A Study of LY3214996 in Healthy Participants | Completed | Eli Lilly and Company | Phase 1 | The main purpose of this study is to measure how much of the study drug gets into the bloodstream and how long it takes the body to get rid of it. This study will involve a single dose of 14C radiolabelled LY3214996. This means that a radioactive substance, C14, will be incorporated into the study drug. The purposes are to investigate the study drug and its breakdown products and to find out how much of these pass from blood into urine and feces. The study will last up to six weeks. |
| NCT04043845 ↗ | ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies | Withdrawn | Eli Lilly and Company | Phase 1 | This research is studying the safety of combining ibrutinib with the study drug LY3214996 for chronic lymphocytic leukemia (CLL), Waldenstrom's macroglobulinemia (WM), mantle cell lymphoma (MCL), or marginal zone lymphoma (MZL). |
| NCT04043845 ↗ | ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies | Withdrawn | Dana-Farber Cancer Institute | Phase 1 | This research is studying the safety of combining ibrutinib with the study drug LY3214996 for chronic lymphocytic leukemia (CLL), Waldenstrom's macroglobulinemia (WM), mantle cell lymphoma (MCL), or marginal zone lymphoma (MZL). |
| NCT04081259 ↗ | LY3214996 in Patients With AML Who Are Not Candidates for Standard Therapy | Recruiting | Eli Lilly and Company | Phase 1 | This research study is evaluating a targeted therapy as a possible treatment for acute myeloid leukemia (AML) that has returned or not responded to standard treatment. |
| NCT04081259 ↗ | LY3214996 in Patients With AML Who Are Not Candidates for Standard Therapy | Recruiting | Dana-Farber Cancer Institute | Phase 1 | This research study is evaluating a targeted therapy as a possible treatment for acute myeloid leukemia (AML) that has returned or not responded to standard treatment. |
| NCT04386057 ↗ | LY3214996 +/- HCQ in Pancreatic Cancer | Recruiting | Eli Lilly and Company | Phase 2 | This study is evaluating the safety and efficacy of combining the study drug LY3214996 with hydroxychloroquine sulfate (HCQ) in patients with advanced pancreatic cancer. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for LY3214996
Condition Name
Clinical Trial Locations for LY3214996
Trials by Country
Clinical Trial Progress for LY3214996
Clinical Trial Phase
Clinical Trial Sponsors for LY3214996
Sponsor Name
